Carlsmed Raises $2.5M to Improve Complex Spine Surgery

June 23, 2020

Carlsmed announced the close of an oversubscribed $2.5M seed round. The round was led by Cove Fund II, a prominent California Life Science and Technology fund.

Carlsmed notes participating in the round are MedTech funds Wavemaker Three-Sixty Health and Device of Tomorrow Capital, as well as individual MedTech investors.

We are very bullish about the prospects for Carlsmed,” said Mike Benvenuti, Co-Manager of Cove Fund II. “Carlsmed’s team has the deep industry experience and operational expertise to lead the much-needed shift to personalized medicine for challenging complex spine cases and beyond.”

“This round of venture financing accelerates the clinical launch of the aprevo™ system,” said Mike Cordonnier, CEO, and co-founder of Carlsmed. “Surgeons and patients across the spectrum that have postponed treatment for debilitating spinal conditions will soon have access to an affordable and streamlined system for personalized spine surgery.”

Today, Carlsmed also announced the appointment of Alexander Arrow, MD, CFA, as Chief Financial Officer and Shariq Hussain as Chief Information Officer, leading the company’s digital development and operations. These two additions to the team are instrumental in building the infrastructure and systems to scale the company to meet the clinical demand.

Dr. Arrow is a MedTech executive with 20+ years of C-suite and financial leadership roles including CFO of Protagenic Therapeutics, Inc. (PTIX), CEO of Zelegent, Inc., and President, COO, and Director of Biolase, Inc. (BIOL). Dr. Arrow also served as Chief Medical Officer of Stanford-affiliated neuroscience company Circuit Therapeutics, Inc., and as CFO of cardiovascular device manufacturer Arstasis, Inc. He also spent two years as CFO of the Patent & License Exchange, Inc. Prior to joining the MedTech industry, he spent nine years in equity research on Wall Street, most recently as head of MedTech research at Lazard, Ltd. He has an M.D. from Harvard Medical School and a B.A. in Biophysics from Cornell University.

Mr. Hussain is a serial entrepreneur in the MedTech industry. As co-founder, and past CEO and CTO, of IntelliGuard, he developed fully integrated hospital inventory management solutions of high-value pharmaceuticals. Previously, he led Systems Integration and Cybersecurity for startup Safety Syringes, which resulted in its successful acquisition by Becton Dickinson. He has a B.S. in Computer Science and Engineering from the University of California San Diego and an M.B.A. from National University.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Kazia has also agreed to issue in a concurrent private placement unregistered warrants to purchase up to an aggregate of 4,444,445 ADSs. The warrants will have an exercise price of $0.583 per ADS, will be immediately exercisable upon issuance, and will expire five and one-half years from the date of issuance. The closing of the offering is expected to occur on or about December 5, 2023, subject to the satisfaction of customary closing conditions.
The groundbreaking ColoSeal System™ enables minimally invasive colorectal tumor removal, eliminating the need for 2 open surgeries in today's standard of care notes Savage Medical.
Alto Neuroscience advises the funds will be used to support ongoing and planned late-stage clinical development of CNS product candidates with four Phase 2 readouts expected across the next 12-18 month
Micron Biomedical has received this grant from the Bill & Melinda Gates Foundation to fund mass production of needle-free vaccines utilizing Micron technology to expand the accessibility of measles-rubella vaccine in developing countries
Ann Lin, co-founder and CEO of Cromatic said, "Outsourcing R&D is one of the most powerful ways for innovative biotech companies to get off the ground. While founders of tech giants like Apple and Google could build their products in garages with minimal resources, founders in biotech are confronted with the capital expense of lab space and equipment and the lengthy process of building the right team before they can even test their ideas. That’s why we are building the most powerful R&D outsourcing platform for biotechs, so that scientists will have clarity, confidence and choice when evaluating and managing their service providers. Ultimately, we want to enable biotech companies to start in garages, just like tech giants.”

By using this website you agree to accept Medical Device News Magazine Privacy Policy